newsfilter
← Latest News
Business Wire·

Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights

– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – – MARIO-P, a study designed to expand eganelisib development in additional solid tumor